<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04702516</url>
  </required_header>
  <id_info>
    <org_study_id>S-20200048</org_study_id>
    <secondary_id>2020-000616-29</secondary_id>
    <secondary_id>0052699</secondary_id>
    <secondary_id>18/51856</secondary_id>
    <secondary_id>A35844</secondary_id>
    <nct_id>NCT04702516</nct_id>
  </id_info>
  <brief_title>The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture</brief_title>
  <official_title>The Effect of Semaglutide (Ozempic) on Bone Turnover in Patients With Increased Fracture Risk: a Randomized Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Morten Frost</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital of South West Jutland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis for this study is that the GLP-1Ra Semaglutide has a positive effect on the&#xD;
      balance between build-up and degradation as well as the strength of the bones in men and&#xD;
      women aged 40-85 years at increased risk of bone fractures. Treatment involves injection of&#xD;
      Semaglutide 1.34 mg/ml once a week or corresponding volume of placebo once a week for 52&#xD;
      weeks. The effect will be measured by bone markers in blood samples, bone scans, bone tissue&#xD;
      tests (bone biopsy), and direct bone strength measured by microindentation at the start and&#xD;
      end of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procollagen type 1 N-terminal propeptide (P1NP)</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Percentage changes in bone formation marker P1NP from baseline and after 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collagen 1 cross link C-terminal telopeptide (CTX)</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Changes in bone resorption marker CTX from baseline and after 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tartrate-resistant acid phosphatase (TRAP)</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Changes in bone resorption marker TRAP from baseline and after 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Changes in bone formation marker osteocalcin from baseline and after 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone specific alkaline phosphatase (BALP)</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Changes in bone formation marker BALP from baseline and after 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMSi</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Changes in direct bone strength measured by microindentation from baseline and after 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density (BMD)</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Changes in BMD (total hip, femoral neck and lumbar spine (L1-4)) assessed by DXA scans from baseline and after 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated bone strength</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Changes in estimated bone strength assessed by finite elemental analysis (HR-pQCT scan) from baseline and after 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total volumetric BMD</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Changes in total volumetric BMD (mg/cm^3) assessed by HR-pQCT scan of distal tibia and radius</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trabecular volumetric BMD</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Changes in trabecular volumetric BMD (mg/cm^3) assessed by HR-pQCT scan of distal tibia and radius</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical volumetric BMD</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Changes in cortical volumetric BMD (mg/cm^3) assessed by HR-pQCT scan of distal tibia and radius</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone volume</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Changes in trabecular bone volume pr total volume (BV/TV) assessed by HR-pQCT scan of distal tibia and radius</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trabecular thickness</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Changes in trabecular thickness (mm) assessed by HR-pQCT scan of distal tibia and radius</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical thickness</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Changes in cortical thickness (mm) assessed by HR-pQCT scan of distal tibia and radius</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical porosity</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Changes in cortical porosity assessed by HR-pQCT scan of tibia and radius</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone formation rate</measure>
    <time_frame>52 weeks</time_frame>
    <description>Changes in bone formation rate (BRF/BS, µm^3/µm^2 per day), the volume of mineralized bone made per unit surface of bone per year</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mirco RNAs</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Changes in expression of blood-circulating microRNAs (miRNAs) known to be involved in regulation of bone formation and bone resorption using qPCR</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>Semaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ozempic 1 mg (or highest tolerated dose) s.c. once weekly for 52 weeks (incl. titration)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (saline) 1 mg (or highest tolerated dose) s.c. once weekly for 52 weeks (incl. titration)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozempic</intervention_name>
    <description>2 mg prefilled pen for subcutaneous injection, 0.25 mg for two weeks then 0.5 mg for two weeks and then 1 mg for another 48 weeks.</description>
    <arm_group_label>Semaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 mg prefilled pen for subcutaneous injection, 0.25 mg for two weeks then 0.5 mg for two weeks and then 1 mg for another 48 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  T-score &lt;-1 in hip or lower back, assessed by DXA scan and / or&#xD;
&#xD;
          -  Low-energy fracture within the last 3 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  T-score &lt;-2.5 in hip or lower back, assessed by DXA scan, although these individuals&#xD;
             may be included if they prefer to participate or are not candidates for conventional&#xD;
             therapy, e.g., by eGFR &lt;35 or adverse reaction (influenza-like symptoms, allergic&#xD;
             reaction, etc.) to, e.g., bisphosphonate therapy&#xD;
&#xD;
          -  Diabetes type 1 and 2&#xD;
&#xD;
          -  Heart failure similar to NYHA Class IV&#xD;
&#xD;
          -  Primary hyperparathyroidism&#xD;
&#xD;
          -  Vitamin D deficiency (&lt;25 nM) (re-test after substitution acceptable)&#xD;
&#xD;
          -  Known disorders affecting bone metabolism, e.g., uncontrolled thyrotoxicosis, severe&#xD;
             renal impairment (eGFR &lt;20) or liver function (baseline phosphatase higher than twice&#xD;
             upper limit (105 U/L)), rheumatism, celiac disease, hypogonadism, severe COPD,&#xD;
             hypopituitarism, Cushing's disease&#xD;
&#xD;
          -  Antiresorptive or bone anabolic drugs for the last 12 months&#xD;
&#xD;
          -  Use of anabolic steroids in the previous year&#xD;
&#xD;
          -  History of pancreatitis&#xD;
&#xD;
          -  Allergy to the medicines used&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  BMI &lt;20 kg / m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten Frost, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Morten Steen Svarer Hansen, MD</last_name>
    <phone>+4521249531</phone>
    <email>morten.steen.hansen@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Morten Frost, MD</last_name>
    <email>mmfnielsen@health.sdu.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <state>Region Of Southern Denmark</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Steen Hansen, MD</last_name>
      <phone>+4521249531</phone>
      <email>morten.steen.hansen@rsyd.dk</email>
    </contact>
    <contact_backup>
      <last_name>Morten Frost, MD</last_name>
      <phone>+4522877448</phone>
      <email>mmfnielsen@health.sdu.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Morten Frost, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Morten Steen Hansen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Morten Frost</investigator_full_name>
    <investigator_title>Associate professor, clinical staff specialist, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

